Current report No. 15/2021 – Signature of an agreement with the National Centre for Research and Development for the co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain

Current reports March 24, 2021

Date: March 24, 2021, 08:36 AM

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) - confidential information.

Content of the report:   

With reference to current report No. 2/2021 of January 18, 2021 on the selection by the National Centre for Research and Development (“NCBR”) for co-financing of the project: “Development and implementation into clinical trials and the company’s activities of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain (GRAPPA)”, submitted to a competition under the Smart Growth Operational Programme 2014-2020, measure 1.1/submeasure 1.1.1, the Management Board of Celon Pharma S.A. hereby informs that on March 23, 2021, it was informed that the National Centre for Research and Development signed the agreement on co-funding of the above-mentioned project.

Pursuant to the co-funding agreement, the total cost of the project amounts to PLN 42.3 million, and the amount of co-funding granted amounts to PLN 22.2 million. The period of cost eligibility for the project ends on December, 31 2023.

Detailed information on the project was provided in the aforementioned current report No. 2/2021.